[ad_1]
CAMBRIDGE, Mbad., June 16, 2019 (GLOBE NEWSWIRE) – VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing vaccines against infectious diseases and immuno-oncology of next generation, will be hosting a teleconference and webcast tomorrow morning, June 17, 2019, at 8:00 ET. Management is pleased to be able to review PROTECT's baseline data, one of two pivotal Phase 3 studies conducted on Sci-B-Vac®, the company's trivalent hepatitis B vaccine.
Details of the teleconference and webcast
Live webcast and slide presentation can be accessed via the Investor section's Events / Presentations page of the company's website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https: / /edge.media-server.com/m6/p/7ryhzgu2.
The webcast will be archived on the company's website for 90 days after the live teleconference.
To listen to the live conference call, dial the following number:
– Free calls to the United States and Canada: (866) 602-1050
– International connection: (409) 231-2052
– Conference ID: 7639339
About Sci-B-Vac®
Sci-B-Vac® is a trivalent vaccine against hepatitis B, whose use is approved in Israel and 10 other countries and is currently the focus of a pivotal program. Phase 3 in the United States, Europe and Canada. This pivotal phase 3 program includes two studies, the PROTECT study and the CONSTANT study. The baseline data from the CONSTANT study are expected by the end of the year 2019. According to data on the distribution of commercial products, more than 500,000 infants and adults have been safely vaccinated with Sci B-Vac® in Israel and in other markets where the vaccine is approved. Unlike second-generation hepatitis B vaccines, which contain only one surface antigen (the S antigen) of hepatitis B virus, Sci-B-Vac® is a trivalent antigen-containing vaccine. S and pre-S1 antigens and S2 pre-surface antigens. Published data demonstrate that T cell responses to pre-S1 and pre-S2 antigens may enhance responses to S antigen, resulting in a more immunogenic response.
About hepatitis B
Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). It is characterized by inflammation of the liver, lesions and cell death. The disease can present itself in an acute way and disappear on its own, or evolve chronically. According to the World Health Organization ("WHO"), more than 880,000 people die each year from HBV-related complications, including cirrhosis and liver cancer, because currently available treatments result in a functional cure in less than 20% of people treated. Primary prevention through vaccination is therefore considered the best way to control hepatitis B infection.
About VBI Vaccines Inc.
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial stage biopharmaceutical company developing a new generation of vaccines to address unmet needs in infectious diseases and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B with the only commercially approved trivalent vaccine against commercially approved hepatitis B, Sci-B-Vac®, approved for use in Israel and Canada. 10 other countries and is currently the subject of a Phase 3 program in the country. The United States, Europe and Canada, and with an immunotherapeutic under development for functional treatment of chronic hepatitis B. VBI's eVLP platform technology allows the development of vaccines to enveloped virus-like particles (eVLPs) that closely mimic the target virus to generate a powerful virus. immune response. Incorporating its cytomegalovirus (CMV) expertise into the eVLP platform technology, the main candidates for VBI's eVLP program include a vaccine candidate for CMV prophylaxis and a glioblastoma immuno-therapeutic candidate (GBM). VBI is headquartered in Cambridge, MA, with research activities in Ottawa, Canada, as well as research and manufacturing facilities in Rehovot, Israel.
Home page: http://www.vbivaccines.com/
News and Ideas: http://www.vbivaccines.com/wire/
Investors: http://www.vbivaccines.com/investors/
Caution regarding forward-looking information
Certain statements in this press release that are forward-looking statements and not statements of historical fact are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and constitute forward-looking information within the meaning of the Canadian law. securities laws (collectively, "forward-looking statements"). The Company wishes to clarify that these statements involve risks and uncertainties that could materially affect the Company's results. These forward-looking statements are based on management's beliefs and the badumptions and information currently available to management. Actual results could differ materially from those contemplated by forward-looking statements as a result of certain factors, including the ability to establish that potential products are effective or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate government approvals or necessary to market potential products; the ability to obtain future financing for development products and working capital and to obtain this financing on commercially reasonable terms; the ability of the company to produce product candidates on a commercial scale or in collaboration with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce the legal rights of the company's products. An badysis of these and other factors, including risks and uncertainties relating to the Company, is presented in the Company's filings with the Securities and Exchange Commission and the Canadian securities regulatory authorities, including including its annual report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2019 and filed with Canadian security authorities on sedar.com on February 25, 2019, as may be supplemented or modified by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on these forward-looking statements, which are qualified in their entirety by this cautionary statement. All forward-looking statements made herein are based on our current expectations and we badume no obligation or obligation to update or revise these forward-looking statements for any reason, except as required by law.
VBI Contact
Nicole Anderson
Partner, Corporate Communications
Phone: (617) 830-3031 ext. 124
Email: [email protected]
VBI investor contact
Nell Beattie
Director of Business
Email: [email protected]
VBI Media Contact
Burns McClellan, Inc.
Robert Flamm, Ph.D.
Telephone: (212) 213-0006
Email: [email protected]
Source link
